Recombinant multi-species Elafin/Skalp/PI3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine Elafin/Skalp/PI3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes an elastase-specific inhibitor that functions as an antimicrobial peptide against Gram-positive and Gram-negative bacteria, and fungal pathogens. The protein contains a WAP-type four-disulfide core (WFDC) domain, and is thus a member of the WFDC domain family. Most WFDC gene members are localized to chromosome 20q12-q13 in two clusters: centromeric and telomeric. This gene belongs to the centromeric cluster. Expression of this gene is upgulated by bacterial lipopolysaccharides and cytokines. [provided by RefSeq, Oct 2014]
The Alternative Names of target: ESI,Elafin,Elastase-specific inhibitor (ESI),PI3,Peptidase inhibitor 3 (PI-3),Protease inhibitor WAP3,SKALP,Skalp,Skin-derived antileukoproteinase (SKALP),TRAPPIN-2,WAP four-disulfide core domain protein 14,WAP3,WFDC14,cementoin,trappin-2

Target products collectionGo to Elafin/Skalp/PI3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE0406-Ag-1/ GM-Tg-hg-SE0406-Ag-2 Human Elafin/Skalp/PI3 protein Human
GM-Tg-rg-SE0406-Ag-1/ GM-Tg-rg-SE0406-Ag-2 Rat Elafin/Skalp/PI3 protein Rat
GM-Tg-mg-SE0406-Ag-1/ GM-Tg-mg-SE0406-Ag-2 Mouse Elafin/Skalp/PI3 protein Mouse
GM-Tg-cynog-SE0406-Ag-1/ GM-Tg-cynog-SE0406-Ag-2 Cynomolgus/Rhesus macaque Elafin/Skalp/PI3 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE0406-Ag-1/ GM-Tg-felg-SE0406-Ag-2 Feline Elafin/Skalp/PI3 protein Feline
GM-Tg-cang-SE0406-Ag-1/ GM-Tg-cang-SE0406-Ag-2 Canine Elafin/Skalp/PI3 protein Canine
GM-Tg-bovg-SE0406-Ag-1/ GM-Tg-bovg-SE0406-Ag-2 Bovine Elafin/Skalp/PI3 protein Bovine
GM-Tg-equg-SE0406-Ag-1/ GM-Tg-equg-SE0406-Ag-2 Equine Elafin/Skalp/PI3 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE0406-Ag-1/ GM-Tg-hg-SE0406-Ag-2; GM-Tg-rg-SE0406-Ag-1/ GM-Tg-rg-SE0406-Ag-2;
GM-Tg-mg-SE0406-Ag-1/ GM-Tg-mg-SE0406-Ag-2; GM-Tg-cynog-SE0406-Ag-1/ GM-Tg-cynog-SE0406-Ag-2;
GM-Tg-felg-SE0406-Ag-1/ GM-Tg-felg-SE0406-Ag-2; GM-Tg-cang-SE0406-Ag-1/ GM-Tg-cang-SE0406-Ag-2;
GM-Tg-bovg-SE0406-Ag-1/ GM-Tg-bovg-SE0406-Ag-2; GM-Tg-equg-SE0406-Ag-1/ GM-Tg-equg-SE0406-Ag-2
Products Name Elafin/Skalp/PI3 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name Elafin/Skalp/PI3
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine Elafin/Skalp/PI3 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.